Differential levels of apolipoprotein E and butyrylcholinesterase show strong association with pathological signs of Alzheimer's disease in the brain in vivo

被引:24
作者
Darreh-Shori, Taher [1 ]
Forsberg, Anton
Modiri, Negar
Andreasen, Niels [2 ]
Blennow, Kaj [3 ]
Kamil, Chelenk
Ahmed, Hiba
Almkvist, Ove [2 ,4 ]
Langstrom, Bengt [5 ]
Nordberg, Agneta [2 ]
机构
[1] Karolinska Inst, Novum, Dept Neurobiol Care Sci & Soc, Div Alzheimer Neurobiol, S-14186 Huddinge, Sweden
[2] Karolinska Univ Hosp Huddinge, Dept Geriatr Med, Stockholm, Sweden
[3] Univ Goteborg, Sahlgrenska Univ Hosp, Dept Neurosci & Physiol, Molndal, Sweden
[4] Stockholm Univ, Dept Psychol, S-10691 Stockholm, Sweden
[5] Uppsala Univ, Dept Organ Chem & Biochem, Uppsala, Sweden
基金
英国医学研究理事会;
关键词
MILD COGNITIVE IMPAIRMENT; CEREBRAL GLUCOSE-METABOLISM; K-VARIANT; E POLYMORPHISM; E EPSILON-4; CHOLINESTERASE ACTIVITY; ACETYLCHOLINE-RELEASE; CEREBROSPINAL-FLUID; AMYLOID DEPOSITION; GENE POLYMORPHISMS;
D O I
10.1016/j.neurobiolaging.2010.04.028
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Recently, we reported that 3 of the known risk factors of Alzheimer's disease (AD), i.e., advanced age, apolipoprotein E (ApoE) epsilon 4, and female gender, are associated with differential levels of ApoE proteins and butyrylcholinesterase (BuChE) in the cerebrospinal fluid (CSF) of AD patients. The ApoE epsilon 4 allele and certain BuChE polymorphisms synergistically affect the conversion rate of mild cognitive impairment (MCI) to AD. Here, we investigated interrelationships between ApoE and BuChE levels, and pathological markers of AD in vivo. CSF from patients with probable AD, assessed for cerebral glucose metabolism (CMRglc; n = 50) and Pittsburgh compound B (PIB) retention (beta-amyloid [A beta] load, n = 29) by positron emission tomography (PET), was used for measurement of BuChE, ApoE, A beta, tau, phosphorylated tau (P-tau) and interleukin-1 beta (IL-1 beta) levels. Levels of ApoE and BuChE strongly correlated with CMRglc (fluorodeoxyglucose [FDG]-PET, r = 0.54, p < 0.0001, n = 50), cerebral A beta load (PIB retention, r = 0.73, p < 0.0001, n = 29), and CSF P-tau (r = 0.73, p < 0.0001, n = 33). High ApoE protein was tied to low CMRglc and high PIB retention and P-tau. BuChE levels had opposite relationships. Other CSF covariates were levels of interleukin-1 beta and A beta(42) peptide. The pattern of the patients' cognitive Z-scores strongly supported these observations. High ApoE protein was also linked to changes in 3 of the biodynamic properties of BuChE. In vitro analysis indicated that high ApoE protein levels were related to an increased pool of dormant BuChE molecules with an abnormally high intrinsic catalytic rate in CSF, which was "turned on" by excess A beta peptides. The findings suggest that abnormally high levels of ApoE may play a causative role in the pathological events of AD, particularly those involving the early cholinergic deficit in the AD brain, through modulation of cholinesterases activities, hence disturbing the acetylcholine-dependent activity of neurons and nonexcitable cells such as glial cells. (C) 2011 Elsevier Inc. All rights reserved.
引用
收藏
页码:2320.e15 / 2320.e32
页数:18
相关论文
共 98 条
[1]   Butyrylcholinesterase activity and metabolic syndrome in obese patients [J].
Alcântara, VM ;
Oliveira, LC ;
Réa, RR ;
Sulplicy, HL ;
Chautard-Freire-Maia, EA .
CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2005, 43 (03) :285-288
[2]   Butyrylcholinesterase activity and risk factors for coronary artery disease [J].
Alcântara, VM ;
Chautard-Freire-Maia, EA ;
Scartezini, M ;
Cerci, MSJ ;
Braun-Prado, K ;
Picheth, G .
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2002, 62 (05) :399-404
[3]  
Aleong R, 2008, CURR ALZHEIMER RES, V5, P33
[4]   Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients [J].
Almkvist, O ;
Darreh-Shori, T ;
Stefanova, E ;
Spiegel, R ;
Nordberg, A .
EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 (04) :253-261
[5]   The butyrylcholinesterase K-variant shows similar cellular protein turnover and quaternary interaction to the wild-type enzyme [J].
Altamirano, CV ;
Bartels, CF ;
Lockridge, O .
JOURNAL OF NEUROCHEMISTRY, 2000, 74 (02) :869-877
[6]   Are there protective treatments for cognitive decline in MS? [J].
Amato, MP ;
Portaccio, E ;
Zipoli, V .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 245 (1-2) :183-186
[7]   CSF biomarkers for mild cognitive impairment and early Alzheimer's disease [J].
Andreasen, N ;
Blennow, K .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2005, 107 (03) :165-173
[8]   CHOLINESTERASE ACTIVITIES IN CEREBROSPINAL-FLUID OF PATIENTS WITH SENILE DEMENTIA OF ALZHEIMER TYPE [J].
APPLEYARD, ME ;
SMITH, AD ;
BERMAN, P ;
WILCOCK, GK ;
ESIRI, MM ;
NEARY, D ;
BOWEN, DM .
BRAIN, 1987, 110 :1309-1322
[9]  
BACKMAN L, 1994, J ABNORM PSYCHOL, V103, P361
[10]   Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy [J].
Bu, Guojun .
NATURE REVIEWS NEUROSCIENCE, 2009, 10 (05) :333-344